Mr. Andréasson, Dr. Archinard and Ms. Diaz currently serve on our remuneration and appointments committee. Dr. Archinard is the chairperson of our remuneration and appointments committee.
Jean-Paul Kress, Chairman
Jean-Paul Kress, was appointed Chairman of our board of directors on June 21, 2019. Jean-Paul Kress is the Chief Executive Officer of Morphosys. He previously served as President and Chief Executive Officer of Syntimmune from January 2018 until its acquisition by Alexion Pharmaceuticals in November 2018. Prior to joining Syntimmune, Jean-Paul Kress served as Executive Vice President, President of International and Head of Global Therapeutic Operations at Biogen Inc. Previously, Jean-Paul Kress served as Senior Vice President, Head of North America at Sanofi Genzyme. From July 2011 to September 2015, Jean-Paul Kress served as President and Chief Executive Officer of Sanofi Pasteur MSD, a leading European vaccine company. Prior to this, Jean-Paul Kress worked at Gilead, Abbvie and Eli Lilly in senior commercial and business development roles in the United States and in Europe. He was a member of Sarepta Therapeutics’ Board of Directors from 2015 until 2017. Jean-Paul Kress holds an M.D. degree from Faculté Necker-Enfants Malades in Paris, and graduate and post-graduate degrees in pharmacology and immunology from École Normale Supérieure in Paris.
Currently, Sven Andreasson is administrator of Galenos. He is the former Chief Executive Officer of Isconova AB (Uppsala, Sweden), CEO of Beta-Cell NV (Brussels), Active Biotech AB (Lund, Sweden) and several companies in the Pharmacia group. He acquired extensive experience in the international biotechnology companies and in the pharmaceutical industry. Sven Andreasson received a BS degree in science and business administration and in Finance from Stockholm School of Economics and Business Administration.
Philippe Archinaud was appointed General Manager, CEO and director of Transgene on 7 December 2004, after 15 years in the BioMerieux group in different positions including management of the US subsidiary. Philippe Archinaud had served as CEO of Innogenetics N.V. since March 2000. He is a chemical engineer and received a PhD in biochemistry from the University of Lyons, with an advanced degree in the PMD management programme from the Harvard Business School.